Tenax Therapeutics (TENX) News Today → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free TENX Stock Alerts $3.67 -0.10 (-2.65%) (As of 05/21/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 1:01 PM | finance.yahoo.comTENX: First Quarter ResultsMay 17, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Tenax Therapeutics, Inc. Reduced by Analyst (NASDAQ:TENX)May 14, 2024 | washingtonpost.comTenax Therapeutics: Q1 Earnings SnapshotMay 14, 2024 | investorplace.comTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024May 14, 2024 | globenewswire.comTenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateApril 30, 2024 | globenewswire.comTenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)April 9, 2024 | finance.yahoo.comTENX: 2023 Financial ResultsApril 9, 2024 | globenewswire.comTenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”March 28, 2024 | benzinga.comTenax Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | msn.comTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023March 28, 2024 | globenewswire.comTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsMarch 20, 2024 | bizjournals.comFormer public company CEO now leads RTP firmMarch 12, 2024 | globenewswire.comTenax Therapeutics to Present at the 36th Annual Roth ConferenceFebruary 29, 2024 | globenewswire.comTenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024February 20, 2024 | finance.yahoo.comTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanFebruary 20, 2024 | globenewswire.comTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanFebruary 12, 2024 | finance.yahoo.comTENX: First Patient EnrolledFebruary 9, 2024 | bizjournals.comChapel Hill pharma pushing PHT treatment opens $9M stock offeringFebruary 8, 2024 | msn.comWhy Tenax Therapeutics (TENX) Stock Is Getting ObliteratedFebruary 8, 2024 | marketwatch.comTenax Therapeutics Shares Plummet Premarket After Stock OfferingFebruary 8, 2024 | markets.businessinsider.comTenax Therapeutics Announces Pricing Of About $9 Mln Offering Of Shares, Warrants; Stock Tanks 63%February 8, 2024 | finance.yahoo.comTenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingFebruary 8, 2024 | investorplace.comWhy Is Tenax Therapeutics (TENX) Stock Down 64% Today?February 8, 2024 | finance.yahoo.comTenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)February 7, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 03:02 PM with a stated reason of "LULD pause." Trading set to resume at 03:02 PM. February 7, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 02:02 PM with a stated reason of "LULD pause."February 7, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | msn.comTenax Therapeutics Granted Patent for Heart Treatment DrugsFebruary 6, 2024 | marketwatch.comTenax Shares Surge After Acceptance of Patent ApplicationFebruary 6, 2024 | msn.comTenax surges after patent win for heart failure therapyFebruary 6, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 09:02 AM with a stated reason of "LULD pause."February 6, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 09:02 AM with a stated reason of "LULD pause."February 6, 2024 | finance.yahoo.comTenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)January 3, 2024 | benzinga.comTenax Therapeutics Stock (NASDAQ:TENX), Short Interest ReportJanuary 3, 2024 | finance.yahoo.comBreakeven On The Horizon For Tenax Therapeutics, Inc. (NASDAQ:TENX)January 3, 2024 | marketbeat.comTrading was temporarily halted for "TENX" at 07:01 PM with a stated reason of "News pending."December 29, 2023 | bizjournals.comChapel Hill public company shrinks share volume by nearly 99%December 4, 2023 | benzinga.comTenax Therapeutics Stock (NASDAQ:TENX) Dividends: History, Yield and DatesNovember 20, 2023 | finance.yahoo.comTENX: IND Clears Way for Phase IIINovember 17, 2023 | finance.yahoo.comTenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory BoardNovember 13, 2023 | investorplace.comWhy Is Tenax Therapeutics (TENX) Stock Up 300% Today?November 13, 2023 | marketwatch.comTenax Therapeutics Shares Double Premarket After FDA Clears IND for TNX-103November 13, 2023 | benzinga.comWhy Tenax Therapeutics (TENX) Stock Is Up 100%November 13, 2023 | finance.yahoo.comTenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023July 19, 2023 | finance.yahoo.comTenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)July 13, 2023 | finance.yahoo.comTENX - Tenax Therapeutics, Inc.May 31, 2023 | tmcnet.comTenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide TENX Media Mentions By Week TENX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TENX News Sentiment▼-0.770.43▲Average Medical News Sentiment TENX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TENX Articles This Week▼61▲TENX Articles Average Week Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vaccinex News Pasithea Therapeutics News Shuttle Pharmaceuticals News Biofrontera News Cadrenal Therapeutics News Pulmatrix News Hepion Pharmaceuticals News ASLAN Pharmaceuticals News Ainos News Hillstream BioPharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TENX) was last updated on 5/22/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchNew Options need New Trading StrategiesNetpicksObama’s Forever Term [exposed]Porter & CompanyTrump’s second term “playbook” leaked?Paradigm PressYou won’t see these trades on TVProsper Trading AcademyThis could mean the end of the U.S dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
